Home › Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes
 

Keywords :   


Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes

2014-02-10 14:43:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Language: English Contact: Merck Media InquiriesKim Hamilton, 908-423-6831orCaroline Lappetito, 267-305-7639orMerck Investor RelationsCarol Ferguson, 908-423-4465orSamsung Media InquiriesHongSeok Ji, +82-32-455-6102orSamsung Investor RelationsSungjoon Park, +82-32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for enter agreement develop

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05ABG announces leadership transition
16.05CeraVe Expands Sun Safety Day Initiative to Offer SPF Education Across the US this Summer
16.05Ex-Post Office IT boss blocked Vennells' number
16.05Covergirls New Eye Enhancer 3D Mascara Makes Eyes Pop
16.05ANEX to be Held in Taiwan Next Week
16.05Gov. Reynolds signs Iowa Meat Integrity Bill
16.05Gov. Reynolds signs Iowa Meat Integrity Bill
16.05Reality TV stars charged over investment plugs
More »